Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT02853695Completed

Implementation of Hysteroscopy in Flanders and the Netherlands

Role: collaborator

NCT00965939Completed

An Observational Study to Assess Response to Tamoxifen in Breast Cancer Patients

Role: lead

NCT00966043Completed

Prevalence of Genetic Polymorphisms in Genes Coding for Tamoxifen Metabolising Enzymes

Role: lead

All 3 trials loaded